Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma

被引:12
作者
Xu, Xuejun [1 ]
Gao, Yifeng [1 ]
Duan, Shanzhou [1 ]
Ding, Qifeng [1 ]
Wang, Xiaofan [1 ]
Dai, Xiaoxiao [2 ]
Zhang, Yongsheng [2 ]
Chen, Yongbing [1 ]
Chen, Donglai [3 ,4 ]
机构
[1] Soochow Univ, Affiliated Hosp 2, Dept Thorac Surg, Suzhou, Peoples R China
[2] Soochow Univ, Affiliated Hosp 2, Dept Pathol, Suzhou, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[4] 180 Fenglin Rd, Shanghai 200032, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 08期
关键词
clinicopathological features; PD-1; prognosis; stage I lung adenocarcinoma; tertiary lymphoid structure; RESPIRATORY SOCIETY CLASSIFICATION; INTERNATIONAL ASSOCIATION; INDEPENDENT PREDICTOR; TIM-3; EXPRESSION; GRADING SYSTEM; B-CELLS; CANCER; TUMOR; IMMUNOTHERAPY; RECURRENCE;
D O I
10.1002/cam4.5731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: We investigated the clinical implications and molecular features of TLS in stage I lung adenocarcinoma (LUAD).Methods: We retrospectively reviewed the clinicopathological characteristics of 540 patients with p-stage I LUAD. Logistic regression analysis was applied to determining the relationships between clinicopathological features and the presence of TLS. TLS-associated immune infiltration pattern and signature genes were characterized using the transcriptomic profiles of 511 LUADs from The Cancer Genome Atlas (TCGA) database.Results: The presence of TLS was associated with a higher pT stage, low- and middle-grade patterns, and the absence of tumor spreading through air spaces (STAS) and subsolid nodules. Multivariate Cox regression analysis identified that the presence of TLS was associated with favorable overall survival (OS) (p < 0.001) and recurrence-free survival (RFS) (p < 0.001). Subgroup analysis showed that the most favorable OS (p < 0.001) and RFS (p < 0.001) favored the TLS + PD-1- subgroup. The presence of TLS was characterized by abundance in antitumor immunocytes including activated CD8+ T and B cells as well as dentritic cells in TCGA cohort.Conclusion: The presence of TLS was an independent favorable factor for patients with stage I LUAD. The presence TLS was featured by special immune profiles which might aid oncologists in determining personalized adjuvant treatment.
引用
收藏
页码:9547 / 9558
页数:12
相关论文
共 50 条
  • [31] Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma
    Kameda, Koji
    Eguchi, Takashi
    Lu, Shaohua
    Qu, Yang
    Tan, Kay See
    Kadota, Kyuichi
    Adusumilli, Prasad S.
    Travis, William D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : 1919 - 1929
  • [32] Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma
    Ahmed, Azaz
    Koehler, Sophia
    Klotz, Rosa
    Giese, Nathalia
    Hackert, Thilo
    Springfeld, Christoph
    Zoernig, Inka
    Jaeger, Dirk
    Halama, Niels
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [33] Pathological features and prognostic implications of ground-glass opacity components on computed tomography for clinical stage I lung adenocarcinoma
    Shinya Katsumata
    Keiju Aokage
    Genichiro Ishii
    Hironobu Hoshino
    Jun Suzuki
    Tomohiro Miyoshi
    Kenta Tane
    Joji Samejima
    Masahiro Tsuboi
    Surgery Today, 2021, 51 : 1188 - 1202
  • [34] Molecular and spatial analysis of tertiary lymphoid structures in Sjogren's syndrome
    Nayar, Saba
    Turner, Jason D.
    Asam, Saba
    Fennell, Eanna
    Pugh, Matthew
    Colafrancesco, Serena
    Berardicurti, Onorina
    Smith, Charlotte G.
    Flint, Joe
    Teodosio, Ana
    Iannizzotto, Valentina
    Gardner, David H.
    van Roon, Joel
    Korsunsky, Ilya
    Howdle, Dawn
    Brenner, Michael
    Coles, Mark
    Powrie, Fiona M.
    Raychaudhuri, Soumya
    Frei, Andreas P.
    Lassen, Kara G.
    Bowman, Simon J.
    Ng, Wan-Fai
    Croft, Adam P.
    Filer, Andrew
    Fisher, Benjamin A.
    Buckley, Christopher D.
    Barone, Francesca
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [35] Clinicopathological, gene expression and genetic features of stage I lung adenocarcinoma with necrosis
    Oiwa, Hiroaki
    Aokage, Keiju
    Suzuki, Ayako
    Sato, Kei
    Kuroe, Takashi
    Mimaki, Sachiyo
    Tane, Kenta
    Miyoshi, Tomohiro
    Samejima, Joji
    Tsuchihara, Katsuya
    Goto, Koichi
    Funai, Kazuhito
    Tsuboi, Masahiro
    Nakai, Tokiko
    Ishii, Genichiro
    LUNG CANCER, 2021, 159 : 74 - 83
  • [36] CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes
    Perez-Johnston, Rocio
    Araujo-Filho, Jose A.
    Connolly, James G.
    Caso, Raul
    Whiting, Karissa
    Tan, Kay See
    Zhou, Jian
    Gibbs, Peter
    Rekhtman, Natasha
    Ginsberg, Michelle S.
    Jones, David R.
    RADIOLOGY, 2022, 303 (03) : 664 - 672
  • [37] Pathological features and prognostic implications of ground-glass opacity components on computed tomography for clinical stage I lung adenocarcinoma
    Katsumata, Shinya
    Aokage, Keiju
    Ishii, Genichiro
    Hoshino, Hironobu
    Suzuki, Jun
    Miyoshi, Tomohiro
    Tane, Kenta
    Samejima, Joji
    Tsuboi, Masahiro
    SURGERY TODAY, 2021, 51 (07) : 1188 - 1202
  • [38] Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components
    Li, Ying
    Zhao, Junfeng
    Zhao, Ying
    Li, Ruyue
    Dong, Xue
    Yao, Xiujing
    Xia, Zhongshuo
    Xu, Yali
    Li, Yintao
    CANCER MEDICINE, 2024, 13 (03):
  • [39] Mature Tertiary Lymphoid Structures in Lung Adenocarcinoma Are Associated With Better Progression Free Survival
    Obeng, R.
    Parihar, V.
    Alexis, D.
    Sica, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S912 - S913
  • [40] Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma
    Yu, Yongfeng
    Ding, Zhengping
    Jian, Hong
    Shen, Lan
    Zhu, Lei
    Lu, Shun
    CANCER MEDICINE, 2016, 5 (09): : 2323 - 2331